Profiling the oral microbiomes in patients with Alzheimer's disease/Experiment 9
From BugSigDB
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- SalivaSaliva
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Alzheimer's diseaseAlzheimer's disease
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Early-onset Alzheimer's Disease patients (EAS)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Late-onset Alzheimer's Disease patients (NAS)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with late-onset Alzheimer's Disease
- Group 0 sample size Number of subjects in the control (unexposed) group
- 10
- Group 1 sample size Number of subjects in the case (exposed) group
- 16
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 3 months
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- PacBio RS
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- Metastats
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
Signature 2
Source: Figure S3d
Description: Differential abundance of bacteria in AD patients with different clinical types
Abundance in Group 1: decreased abundance in Late-onset Alzheimer's Disease patients (NAS)
